Publications scientifiques en oncologie

The peptide-drug conjugate TH1902 inhibits growth of subcutaneous melanoma xenografts and formation of lung metastases in a syngeneic mouse model
2022
Michel Demeule, Jean-Christophe Currie, Cyndia Charfi, Alain Larocque, Alain Zgheib, Sophie Kozelko, Richard Béliveau, Christian Marsolais, Borhane Annabi.
TH1902, a SORT1 docetaxel peptide-drug conjugate, inhibits tumor growth of human cancer stem-like cells (CD133+) from both triple-negative breast cancers and ovarian cancers
2022
Christian Marsolais, Cyndia Charfi, Michel Demeule, Jean-Christophe Currie, Alain Zgheib, Alain Larocque, Richard Béliveau, Borhane Annabi
Anti-cancer efficacy of TH1902, a SORT1 docetaxel peptide-drug conjugate, against ovarian and endometrial cancers xenografts alone or in combination with carboplatin”
2022
Christian Marsolais, Michel Demeule, Cyndia Charfi, Jean-Christophe Currie, Alain Larocque, Alain Zgheib, Richard Béliveau, Borhane Annabi.
Achieving virological control in pan-resistant HIV-1 infection: A case series
2022
Diana Canetti, Camilla Muccini, Vincenzo Spagnuolo, Laura Galli, Andrea Poli, Nicola Gianotti, Marcello Feasi, and Antonella Castagna,
Vol 77 Month March, 2022 11
TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer
2021
Author  Demeule M, Charfi C, Currie JC, Laroque A, Zgheib A, Kozelko S, Béliveau R, Marsolais C, Annabi B 
Demeule M, Charfi C, Currie J-C, et al. TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer. Cancer Sci. 2021;00:1–18.